出血性疾患の診断市場：診断検査、適応症、最終用途別- 2025～2030年の世界予測

出血性疾患の診断市場は、2023年に6億6,287万米ドルと評価され、2024年には7億1,026万米ドルに達すると予測され、CAGR 7.60%で成長し、2030年には11億709万米ドルに達すると予測されています。

出血性疾患の診断市場には、血友病、フォンウィルブランド病、血小板機能障害などの出血性疾患の検出と診断に使用されるさまざまな検査やツールが含まれます。正確な診断の必要性は、これらの疾患の早期発見、効果的な管理、合併症の予防の必要性によってもたらされます。その用途は主に、病院や専門診断センターにおける検査室ベースの凝固検査、遺伝子検査、出血評価の利用に集中しています。これらの診断から恩恵を受けるエンドユーザーには、より良い治療結果を求める患者のニーズに応える医療プロバイダーや、医薬品開発や臨床検査に注力する製薬会社などが含まれます。

主要成長要因としては、遺伝性疾患の増加、出血性疾患に対する意識の高まり、ポイントオブケア検査や自動化などの診断技術の進歩などが挙げられます。新興国における医療インフラの拡充は、診断精度を高めるためのゲノムとプロテオミクス・アプローチの精緻化と同様に、有利な機会をもたらしています。企業は個別化医療に注力し、費用対効果の高い迅速診断ソリューションを開発することで、市場を開拓することができます。課題としては、先進的検査にかかるコストの高さ、特定地域での認知度の低さ、規制当局の認可の厳しさなどが挙げられます。

分子診断学とバイオインフォマティクスの革新は、研究と事業拡大の有望な道を記載しています。出血性疾患を早期かつ正確に同定するための新規バイオマーカーを開発するための研究開発に重点を置くことが重要です。さらに、研究機関との協力関係を促進し、診断のためのAI主導ツールに投資することが成長を促進する可能性があります。同市場は、既存の医療大手とニッチセグメントに注力する新興参入企業の両方が大きな関心を寄せており、競争的な性質を示しています。しかし、規制状況の克服と幅広いアクセシビリティの確保は、依然として根強い課題です。企業は、市場への浸透を強化し競争優位性を維持するために、手頃な価格の検査ソリューションと戦略的パートナーシップを優先すべきです。

市場力学：急速に進化する出血性疾患の診断市場における主要市場洞察の解明

出血性疾患の診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 出血性疾患の有病率の増加
  • 一般人口と医療専門家の間での出血性疾患に対する認識と取り組みの高まり
• 市場抑制要因
  • 先進的出血性疾患の診断手法に関連する高コスト
• 市場機会
  • 出血性疾患の診断における先端技術の新たな可能性
  • ポイントオブケア出血性疾患検査機器の採用拡大
• 市場課題
  • 規制の複雑さと地域によって異なる医療規制のダイナミックな性質

ポーターのファイブフォース：出血性疾患の診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：出血性疾患の診断市場における外部からの影響の把握

外部マクロ環境要因は、出血性疾患の診断市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：出血性疾患の診断市場における競合情勢の把握

出血性疾患の診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：出血性疾患の診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、出血性疾患の診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：出血性疾患の診断市場における成功への道筋を描く

出血性疾患の診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 出血性疾患の罹患率の増加
    • 一般の人々と医療従事者の間で出血性疾患に関する認識と取り組みが高まっている
  • 抑制要因
    • 先進的出血性疾患の診断メソッドに関連する高コスト
  • 機会
    • 出血性疾患の診断における先端技術の新たな可能性
    • ポイントオブケア出血性疾患検査装置の導入拡大
  • 課題
    • さまざまな地域における医療規制の複雑さと動的な性質
• 市場セグメンテーション分析
  • 診断検査：凝固因子に関連する特定の遺伝子の変異や異常を特定するための遺伝子検査の重要性が高まっている
  • 適応症：さまざまなタイプのVWDを診断するための出血性疾患の診断の重要な用途
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 出血性疾患の診断市場：診断検査別

• イントロダクション
• 出血時間
• 遺伝子検査
• 血小板凝集検査

第7章 出血性疾患の診断市場：適応症別

• イントロダクション
• 血友病Aと血友病B
• 血小板機能障害
• フォン・ヴィレブランド病

第8章 出血性疾患の診断市場：最終用途別

• イントロダクション
• 診断ラボ
• 病院
• 専門クリニック

第9章 南北アメリカの出血性疾患の診断市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の出血性疾患の診断市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの出血性疾患の診断市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • ARUP Laboratories、血友病Aの診断検査で歴史を築く
  • FDA、重症血友病Aの成人患者に対する初の遺伝子治療を承認
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• ARUP Laboratories
• Baxter International Inc.
• Bayer AG
• Bio-Rad Laboratories, Inc.
• Cepheid by Danaher Corporation
• CSL Limited
• F. Hoffmann-La Roche Ltd.
• HORIBA, Ltd.
• Hyphen BioMed by Sysmex Corporation
• Laboratory Corporation of America Holdings
• Novo Nordisk A/S
• Precision BioLogic
• rHEALTH
• Siemens AG
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. BLEEDING DISORDER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BLEEDING DISORDER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BLEEDING DISORDER DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLEEDING TIME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A & HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 30. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 47. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 50. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 102. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 114. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 117. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 146. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Bleeding Disorder Diagnostics Market was valued at USD 662.87 million in 2023, expected to reach USD 710.26 million in 2024, and is projected to grow at a CAGR of 7.60%, to USD 1,107.09 million by 2030.

The bleeding disorder diagnostics market encompasses a range of tests and tools used to detect and diagnose bleeding disorders, such as hemophilia, Von Willebrand disease, and platelet function disorders. The necessity for precise diagnostics is driven by the need for early detection, effective management, and prevention of complications associated with these conditions. Applications primarily revolve around the use of laboratory-based coagulation tests, genetic testing, and bleeding assessments in hospitals and specialized diagnostic centers. End-users benefit from these diagnostics include healthcare providers catering to patient needs for better treatment outcomes and pharmaceutical companies focusing on drug development and clinical trials.

Key growth factors include the rise in genetic disorders, increasing awareness of bleeding disorders, and advancements in diagnostic technologies such as point-of-care testing and automation. Expanding healthcare infrastructure in emerging economies presents lucrative opportunities, as does the refinement in genomic and proteomic approaches to enhance diagnostic accuracy. Companies can tap into the market by focusing on personalized medicine and developing cost-effective, rapid diagnostic solutions. Challenges include high costs of advanced tests, limited awareness in certain regions, and strict regulatory approvals.

Innovations in molecular diagnostics and bioinformatics offer promising avenues for research and business expansion. Emphasis on R&D to develop novel biomarkers for early and precise identification of bleeding disorders is critical. Additionally, fostering collaborations with research institutions and investing in AI-driven tools for diagnostics can drive growth. The market shows a competitive nature with substantial interest from both established healthcare giants and emerging players focusing on niche areas. However, navigating regulatory landscapes and ensuring broad accessibility remain persistent challenges. Companies should prioritize affordable test solutions and strategic partnerships to enhance market penetration and sustain competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bleeding Disorder Diagnostics Market

The Bleeding Disorder Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of bleeding disorders
  • Growing awareness and initiatives about bleeding disorders among the general population and healthcare professionals
• Market Restraints
  • High costs associated with advanced bleeding disorder diagnostics methods
• Market Opportunities
  • Emerging potential of advanced technologies in bleeding disorder diagnostics
  • Growing adoption of point-of-care bleeding disorder testing devices
• Market Challenges
  • Regulatory complexities and the dynamic nature of healthcare regulations across different regions

Porter's Five Forces: A Strategic Tool for Navigating the Bleeding Disorder Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bleeding Disorder Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bleeding Disorder Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bleeding Disorder Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bleeding Disorder Diagnostics Market

A detailed market share analysis in the Bleeding Disorder Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bleeding Disorder Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bleeding Disorder Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bleeding Disorder Diagnostics Market

A strategic analysis of the Bleeding Disorder Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bleeding Disorder Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Baxter International Inc., Bayer AG, Bio-Rad Laboratories, Inc., Cepheid by Danaher Corporation, CSL Limited, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Hyphen BioMed by Sysmex Corporation, Laboratory Corporation of America Holdings, Novo Nordisk A/S, Precision BioLogic, rHEALTH, Siemens AG, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorder Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Diagnostic Tests, market is studied across Bleeding Time, Genetic Tests, and Platelet Aggregation Tests.
• Based on Indication, market is studied across Hemophilia A & Hemophilia B, Platelet Function Disorders, and Von Willebrand Disease.
• Based on End-use, market is studied across Diagnostic Laboratories, Hospitals, and Specialized Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of bleeding disorders
    • 5.1.1.2. Growing awareness and initiatives about bleeding disorders among the general population and healthcare professionals
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with advanced bleeding disorder diagnostics methods
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging potential of advanced technologies in bleeding disorder diagnostics
    • 5.1.3.2. Growing adoption of point-of-care bleeding disorder testing devices
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory complexities and the dynamic nature of healthcare regulations across different regions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Diagnostic Tests: Growing importance of genetic testing to identify mutations or abnormalities in specific genes associated with clotting factors
  • 5.2.2. Indication: Significant applications of bleeding disorder diagnostics to diagnose different types of VWD
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bleeding Disorder Diagnostics Market, by Diagnostic Tests

• 6.1. Introduction
• 6.2. Bleeding Time
• 6.3. Genetic Tests
• 6.4. Platelet Aggregation Tests

7. Bleeding Disorder Diagnostics Market, by Indication

• 7.1. Introduction
• 7.2. Hemophilia A & Hemophilia B
• 7.3. Platelet Function Disorders
• 7.4. Von Willebrand Disease

8. Bleeding Disorder Diagnostics Market, by End-use

• 8.1. Introduction
• 8.2. Diagnostic Laboratories
• 8.3. Hospitals
• 8.4. Specialized Clinics

9. Americas Bleeding Disorder Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bleeding Disorder Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bleeding Disorder Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. ARUP Laboratories Makes History with Diagnostic Test for Hemophilia A
  • 12.3.2. FDA Approves First Gene Therapy for Adults with Severe Hemophilia A
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ARUP Laboratories
• 3. Baxter International Inc.
• 4. Bayer AG
• 5. Bio-Rad Laboratories, Inc.
• 6. Cepheid by Danaher Corporation
• 7. CSL Limited
• 8. F. Hoffmann-La Roche Ltd.
• 9. HORIBA, Ltd.
• 10. Hyphen BioMed by Sysmex Corporation
• 11. Laboratory Corporation of America Holdings
• 12. Novo Nordisk A/S
• 13. Precision BioLogic
• 14. rHEALTH
• 15. Siemens AG
• 16. Takeda Pharmaceutical Company Limited
• 17. Thermo Fisher Scientific Inc.